There’s also news from Brisbane, Adelaide and a significant phase II clinical trial.
Digital referral specialist Consultmed has launched its integration with Best Practice (BP) Software, now powered by Halo Connect – a secure, cloud-based platform leveraging FHIR standards for seamless data exchange and interoperability.
The Consultmed integration with BP enables GPs and other healthcare providers to generate and send referrals directly from their patient management software, eliminating the need for re-entering patient details.
With Halo Connect’s secure APIs and server-level connectivity, the integration enhances workflows, reduces repetitive data entry and minimises administrative errors. Referrals are automatically stored in the patient’s file within BP Premier, ensuring accurate and efficient record-keeping.
“Clear communication between healthcare providers is vital for quality patient care,” Lindsay Moore, project manager at Consultmed and experienced optometrist, emphasised.
“This integration streamlines a critical part of the process, making it more efficient for clinicians and ultimately improving patient outcomes.”
Vaxxas wins US prize to advance microarray patches
Brisbane-based clinical-stage biotechnology company Vaxxas has been named a concept stage winner of the US Biomedical Advanced Research and Development Authority’s (BARDA’s) $50 million Patch Forward Prize.
Vaxxas will receive $3.2 million from BARDA to accelerate its work advancing the company’s high-density microarray patch technology for administration of a covid mRNA vaccine.
Vaxxas will collaborate with the University of Queensland’s mRNA research and manufacturing BASE facility, a co-applicant on Vaxxas’ application, to advance this program during 2025.
“We’re honoured to have our world-leading microarray patch technology chosen to be part of this important BARDA-led public health initiative to accelerate new vaccine technologies,” said David Hoey, president and CEO of Vaxxas.
“We’re excited about the potential for our technology to play an important role in effectively protecting populations against dangerous respiratory infectious diseases such as influenza and covid.”
Vaxxas is currently conducting an IND-enabled Phase I clinical study with BARDA for a pre-pandemic influenza vaccine involving 258 participants. Additionally, the company has shown promising results in initial HD-MAP/mRNA work funded by the Coalition for Epidemic Preparedness Innovations.
Alcidion teams up with Northern Adelaide LHN
Alcidion’s Miya Precision and mobile clinical task management solutions will be implemented across the Northern Adelaide Local Health Network, one of the largest LHNs in South Australia.
The deployment of Miya Precision will support real-time patient flow management, command centre operations, secure clinical task management and messaging, and mobile access to real-time data.
Miya Precision will be integrated with SA Health’s electronic patient record and other clinical applications delivering a streamlined view of each patient’s journey across NALHN facilities.
Visibility of real-time demand and capacity will support improvements to patient flow across the system.
This contract holds special significance for Alcidion – Adelaide is where Alcidion was founded almost 25 years ago. For NALHN, this represents the opportunity to take advantage of the full capabilities of Miya Precision to improve the clinician and patient experience.
Alcidion CEO and MD Kate Quirke said:
“This contract represents a significant milestone for Alcidion, enabling us to support critical health information systems in the state of South Australia – where our company was founded.
“Alcidion has a large team based in Adelaide who are excited to start work on this project.
“Our focused goal is to improve workflow efficiencies and health outcomes for their patients, which we hope will inform and inspire the highest standards of care for all Australian healthcare providers.”
Recce’s clinical trial advances
ASX-listed Recce Pharmaceuticals, currently developing a new class of synthetic anti-infectives, has announced the successful dosing of all 30 patients in its phase II clinical trial of RECCE® 327 topical gel (R327G) for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
The phase II clinical trial is an open-label study to evaluate the safety and tolerability, plasma pharmacokinetics and efficacy of R327G; applied once daily for seven or 14 days to areas infected by ABSSSI.
Interim data has demonstrated there were no serious adverse events (SAEs) with R327G’s efficacy and safety profile, and patients dosed achieving positive outcomes. Full results will be available at the end of this quarter.